P3.02-022 Protein Tyrosine Phosphatase Interacting Protein 51 Might Improve EGFR-TKI Sensitivity in Non-Small-Cell Lung Cancer

Abstract

Epidermal growth factor receptor (EGFR) -mutant tumors define a subset of Non-small-cell lung cancer (NSCLC), tumors that harbor EGFR mutation are highly sensitive to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib. However, acquired resistance develops in most NSCLC patients with EGFR mutations after 10-14 months of treatment. In this study we aimed to testify the tumor suppressing function of Protein tyrosine phosphatase interacting protein 51 (PTPIP51), an apoptosis related protein and its effect in improving EGFR-TKI sensitivity.